Protocol NRG-HN002, Nearing Accrual Target

NRG-HN002, “A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer,” is nearing its accrual target. Please refer to the CTSU website for current accrual. When this study reaches target accrual, NRG Oncology will send a follow-up closure notice alerting sites that the protocol will close in 2 business days.

Reminder: Data collection and site IRB renewal for closed studies must continue until the study is terminated.

Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103